论文部分内容阅读
目的探讨胸苷酸合成酶(TS)、核苷酸切除修复交叉互补基因1(ERCC1)及拓扑异构酶-Ⅱ(TopoⅡ)在结直肠癌中的表达及临床意义。方法选择本院2011年5月—2013年5月接受结直肠癌根治性手术的90例患者,应用SP免疫组化联合检测TS、ERCC1及TopoⅡ在结直肠癌组织和对照组20例正常结直肠组织中的表达,并结合临床病理因素进行分析。结果①TS、ERCC1在结直肠癌组织中的表达高于正常结直肠黏膜组织,TopoⅡ在结直肠癌组织中低表达(P<0.05);②TS表达与年龄有关,在≥60岁患者组中表达低于<60岁组;③ERCC1表达与不同病理类型有关,而与肿瘤分化程度及淋巴结转移无关;④TopoⅡ表达与结直肠癌的病理类型及分化程度均有关(P<0.05),而与浸润深度及淋巴结转移无关。结论 TS、ERCC1及TopoⅡ均在结直肠癌对抗肿瘤药物耐药中起重要作用。联合检测TS、ERCC1及TopoⅡ对于结直肠癌判断预后、制定化疗方案有一定的指导意义。
Objective To investigate the expression and clinical significance of thymidylate synthase (TS), nucleotide excision repair cross-complementation gene 1 (ERCC1) and topoisomerase-II (TopoII) in colorectal cancer. Methods A total of 90 patients undergoing radical resection of colorectal cancer from May 2011 to May 2013 were enrolled. SP immunohistochemistry was used to detect TS, ERCC1 and Topo II in colorectal cancer tissues and control group. Normal colorectal cancer was performed in 20 patients. Expression in the tissue, combined with clinical pathological factors. Results The expression of TS and ERCC1 in colorectal cancer tissue was higher than that in normal colorectal mucosa. TopoII was low expressed in colorectal cancer tissue (P<0.05); 2TS expression was age-related, and it was low in ≥60-year-old patient group. In the <60-year-old group; 3ERCC1 expression was associated with different pathological types, but not with tumor differentiation and lymph node metastasis; 4TopoII expression was associated with the pathological type and differentiation of colorectal cancer (P < 0.05), and depth of invasion and lymph nodes Transfer is irrelevant. Conclusion TS, ERCC1 and TopoII all play an important role in the antitumor drug resistance of colorectal cancer. Combined detection of TS, ERCC1, and TopoII has certain guiding significance for judging prognosis and formulating chemotherapy regimens for colorectal cancer.